Guangzhou Today, China Tomorrow? A Closer Look At Reimbursement Pilots For Iressa, Tarceva
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca CEO Pascal Soriot sees tremendous potential for Iressa in China, where Roche’s Herceptin grew over 20% in 2012. Both companies have their high-priced targeted therapies in China’s first-ever reimbursement pilot in Guangzhou.
You may also be interested in...
Insider Analysis From Easton Associates: Are Patient Assistance Programs The Silver Bullet To Meet Affordability Challenges In China?
By Celia Deng, Zhiyi Tong and Paul Zhang
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.